The value of protective isolation in preventing nosocomial infections in high risk patients

The American Journal of Medicine
P A Pizzo

Abstract

Since infection is a major cause of death in the patient whose immune responses have been compromised (immunocompromised patient), considerable attention has been focused on developing methods for the prevention of infection. This has primarily been directed at suppressing or eliminating the host's endogenous microbial burden and in decreasing the acquisition of new organisms. The prevention techniques which have been employed vary in complexity from single-room isolation to elaborate systems utilizing air-filtration and decontamination. The most sophisticated of these regimens is the total protected environment (TPE) consisting of a high-efficiency-particulate-air (HEPA)-filtered laminar air flow room which is surface disinfected and in which the patient is fully decontaminated with oral nonabsorbable antibiotics, cutaneous antisepsis, orificial antibiotics and a semisterile diet. The cumulative data to data have shown that the TPE affords a significant (albeit incomplete) reduction in the incidence of serious infections in severely compromised patients. Such protection from infection permits the delivery of novel therapies which might have been precluded because of consequent hematologic or immunologic toxicity. Nonetheless, ...Continue Reading

References

Jun 1, 1978·Antimicrobial Agents and Chemotherapy·D M HahnP H Wiernik
Jan 1, 1979·Medicine·D J WinstonL S Young
Dec 29, 1977·The New England Journal of Medicine·W T HughesS L George
Dec 1, 1972·The Journal of Hygiene·D van der WaaijJ E Lekkerkerk
Nov 14, 1969·Science·D S ZaharkoV T Oliverio
Aug 1, 1970·The American Journal of the Medical Sciences·G P Bodey
Jan 31, 1980·The New England Journal of Medicine·G H LymanD Preston
Feb 21, 1980·The New England Journal of Medicine·J M LeclairD A Goldmann

❮ Previous
Next ❯

Citations

Jan 1, 1989·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·G du Moulin
Jun 11, 1981·The New England Journal of Medicine·P A Pizzo
Aug 30, 2008·Clinical Nurse Specialist CNS·Jame Restau, Angela P Clark
Jan 1, 1996·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·J S Garner
Dec 20, 2008·The Lancet Infectious Diseases·Agata SchlesingerLeonard Leibovici
Feb 1, 1997·American Journal of Infection Control·S Pirwitz, F Manian
Mar 7, 2006·Oncology Nursing Forum·Debra DeMilleLinda A Jacobs
Jul 15, 2004·Oncology Nursing Forum·Elaine Larson, Anita Nirenberg
Dec 18, 2001·Chest·P Eggimann, D Pittet
Feb 6, 2004·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Hiroyuki SugaharaYuzuru Kanakura
Jul 1, 1983·JPEN. Journal of Parenteral and Enteral Nutrition·S N Aker, C L Cheney
Dec 16, 1998·Medizinische Klinik·P HartenN Schmitz

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.